A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Disease Related
• •Age \> 50 years at migraine onset or \> 65 years at CM onset
• •History of hemiplegic migraine, cluster headache or other trigeminal autonomic cephalalgia
• •Current concomitant diagnosis of a secondary type of headache other than MOH
• •No therapeutic response in prevention of migraine after an adequate therapeutic trial of \> 3 preventive treatment categories
• •Changes in drug regimen (ie, changes in dose or frequency of use) of an allowed migraine preventive medication within 2 months prior to start of baseline
• •Received botulinum toxin in the head and/or neck region within 4 months prior to screening
• •Documented history of treatment with an anti-calcitonin gene-related peptide product preventive treatment
• •Anticipated to require any excluded medication/device or procedure during the study
• •Other Medical Conditions
• •History or evidence of unstable or clinically significant medical condition that, in the opinion of the investigator or Amgen's physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion
• •Evidence of "recreational use" of illicit drugs within 12 months prior to screening, based on medical records, self-report, or a positive drug test performed during screening.
• •Study Procedures
• •Changed or planning to change the dose of an allowed concomitant medication that may have migraine preventive effect during baseline period or post-randomization
• •Unstable or clinically significant medical condition that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion
• •Contraception, pregnancy or breastfeeding
• •Unwillingness to maintain acceptable contraception method, when applicable
• •Evidence of pregnancy or breastfeeding per participant self-report, medical records or positivity on baseline pregnancy screening tests, through end of study